Edition:
United States

Circassia Pharmaceuticals PLC (CIRCI.L)

CIRCI.L on London Stock Exchange

87.00GBp
23 Oct 2017
Change (% chg)

2.00 (+2.35%)
Prev Close
85.00
Open
86.00
Day's High
87.00
Day's Low
85.00
Volume
15,848
Avg. Vol
243,654
52-wk High
114.00
52-wk Low
76.75

Latest Key Developments (Source: Significant Developments)

Circassia Pharmaceuticals says H1 revenues up 65 pct to 18.3 mln pounds
Wednesday, 27 Sep 2017 02:00am EDT 

Sept 27 (Reuters) - CIRCASSIA PHARMACEUTICALS PLC ::H1 REVENUE OF 18.3 MILLION STG VERSUS 11.1 MILLION STG YEAR AGO.H1 RESEARCH AND DEVELOPMENT EXPENDITURE OF 27.2 MILLION STG VERSUS 25.1 MILLION STG YEAR AGO.H1 NIOX SALES GROWTH 19 PERCENT (8% AT CER 3 ) TO £13.1 MILLION​.‍IN KEY US MARKET, TARGETING A SUBSTANTIALLY LARGER CUSTOMER BASE THAN AT THIS TIME LAST YEAR​.H1 GROUP LOSS BEFORE TAX OF 39.6 MILLION STG VERSUS LOSS OF 107.6 MILLION STG YEAR AGO.‍"ANTICIPATE ROBUST REVENUE GROWTH FOR BOTH NIOX AND TUDORZA"​.‍PARTNER ASTRAZENECA IS ON TRACK TO SUBMIT AN NDA FOR DUAKLIR IN FIRST HALF OF 2018​.  Full Article

Circassia Pharmaceuticals fy revenues increased to 23.1 mln stg
Tuesday, 25 Apr 2017 02:00am EDT 

April 25 (Reuters) - Circassia Pharmaceuticals Plc ::Preliminary results for year ended 31 December 2016.FY revenues increased to £23.1 million (2015: £10.8 million).FY research and development investment £46.2 million (2015: £46.8 million) including allergy expenditure of £21.5 million.FY underlying loss for year £57.4 million (2015: £50.0 million); total loss £137.4 million (2015: £50.0 million).Fy allergy portfolio provisions, restructuring costs and impairments £80.0 million 4 (2015: £nil).Strong balance sheet with £117.4 million cash 5 at 31 december 2016 (31 december 2015: £203.8 million with £33.2 million relating to 2015 acquisitions paid during 2016).  Full Article

Circassia to secure certain U.S. commercial rights to Tudorza, Duaklir from AstraZeneca
Friday, 17 Mar 2017 03:00am EDT 

Circassia Pharmaceuticals Plc : Proposed collaboration and securing of certain U.S. Commercial rights to Tudorza And Duaklir from Astrazeneca . Deal for consideration of up to us$230 million . Deal includes US$50 million in ordinary shares plus future royalties based on Duaklir sales . Intends to fund deferred and contingent consideration through third-party financing . Circassia will make research and development contributions of up to US$62.5 million payable to Astrazeneca as deferred payments . Intends to fund research and development contributions through its returns from commercial collaboration and profit share with Astrazeneca .Deal anticipated to be earnings enhancing for Circassia after one year and broadly cash neutral for three years, then cash generative.  Full Article

Circassia Pharma says 80.47 pct shareholders at AGM vote to approve directors' pay report
Wednesday, 18 May 2016 12:28pm EDT 

Circassia Pharmaceuticals Plc :Says 80.47 percent shareholders present at AGM vote to approve directors' remuneration report; 19.53 percent against.  Full Article